18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

Key Points Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and the company's growth prospects appear to support their enthusiasm. There are a couple of things to watch with Alnylam, though, that could change the outlook for its stock. 10 stocks we like better than Alnylam Pharmaceuticals › There's good news and bad news if you own shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) . The good news is that the biotech stock is up around 25% since the end of July. The bad news is that Alnylam is still down 35% year-to-date, even with that rebound. Ouch. Has Wall Street soured on Alnylam? Not at all.